The mesorectum in rectal cancer surgery – the clue to pelvic recurrence?Br J Surg, 69:10 (1982), 613–16., , and
The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorectal Dis, 3:2 (1988), 127–31. and
Recurrence and survival after total mesorectal excision for rectal cancer. Lancet, 1:8496 (1986), 1479–82. and
Local recurrence after mesorectal excision for rectal cancer. Eur J Surg Oncol, 28:2 (2002), 126–34., , , , and
Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol, 25:4 (1999), 368–74., , , et al.
Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med, 336:14 (1997), 980–7.
Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol, 23:24 (2005), 5644–50., , , et al.
Mesorectal excision for rectal cancer. Lancet, 341:8843 (1993), 457–60., , and
Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg, 181:4 (1995), 335–46., , , and
Mesorectal excision for rectal cancer. Br J Surg, 83:2 (1996), 214–16.
Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg, 133:8 (1998), 894–9., , , , and
Local recurrence following total mesorectal excision for rectal cancer. Br J Surg, 83:3 (1996), 375–9., , , and
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345:9 (2001), 638–46., , , et al.
Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet, 344:8922 (1994), 573–8., , , et al.
Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg, 89:9 (2002), 1142–9., , and
Long term results, toxicity and quality of life in the TME trial. Proc Am Soc Clin Oncol, 23: 16 Suppl. (2005)., , , et al.
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol, 22:10 (2004), 1785–96., , , et al.
Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol, 26:3 (2002), 350–7., , , van de , and van
Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg, 89:3 (2002), 327–34., , , et al.
The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg, 242:1 (2005), 74–82., , , et al.
Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. Cancer, 78:3 (1996), 403–8., , , et al.
Recurrence rates after curative surgery for rectal carcinoma, with special reference to their accuracy. Dis Colon Rectum, 30:6 (1987), 431–4., , and
Patterns of recurrence following curative resection alone for adenocarcinoma of the rectum and sigmoid colon. Cancer, 48:6 (1981), 1492–5., , , et al.
Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy. Int J Radiat Oncol Biol Phys, 9:7 (1983), 977–85., , and
Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer, 37:6 (1976), 2861–5., , and
Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer, 53:6 (1984), 1354–62., , , , and
Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: implications for radiotherapy field design. Int J Radiat Oncol Biol Phys, 55:1 (2003), 138–43., , , et al.
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol, 16:4 (2005), 549–57., , , et al.
Patterns of pelvic recurrence in patients with rectal cancers treated with adjuvant chemotherapy in a multicentre randomised study. Proc Am Soc Clin Oncol, 23:16 suppl. (2005)., , , , and
Hydronephrosis as a prognostic factor in pelvic recurrence from rectal and colon carcinomas. Am J Surg, 190:1 (2005), 55–60., , and
Is there a role for curative surgery for pelvic recurrence from rectal carcinoma in the presence of hydronephrosis?Am J Surg, 182:3 (2001), 274–7., , and
Management of ureteral obstruction produced by recurrent cancer of the rectosigmoid colon. Surg Gynecol Obstet, 110 (1960), 413–18. and
Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med, 312:23 (1985), 1465–72.
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med, 324:11 (1991), 709–15., , , et al.
Survival after postoperative combination treatment of rectal cancer. N Engl J Med, 315:20 (1986), 1294–5., , , et al.
QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc Am Soc Clin Oncol, 22:14 suppl. (2004)., , , et al.
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst, 80:1 (1988), 21–9., , , et al.
Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet, 358:9290 (2001), 1291–304.
The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm colorectal cancer study group. Cancer, 75:9 (1995), 2269–75., , , and
The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer, 92:4 (2001), 896–902., , , , and
Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA, 284:8 (2000), 1008–15., , , et al.
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351:17 (2004), 1731–40., , , et al.
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results – EORTC 22921. J Clin Oncol, 23:24 (2005), 5620–7., , , et al.
Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. Proc Am Soc Clin Oncol, 23:16 suppl. (2005)., , , et al.
Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3–4 rectal cancers: results of the FFCD 9203 randomized trial. Proc Am Soc Clin Oncol, 23:16 suppl. (2005)., , , et al.
Local recurrence following ‘curative’ surgery for large bowel cancer: I. The overall picture. Br J Surg, 71:1 (1984), 12–16., , , , and
Almost all five year disease free survivors are cured following rectal cancer surgery, but longer term follow-up detects some late local and systemic recurrences. Colorectal Dis, 7:4 (2005), 403–5., , , et al.
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from intergroup study 0114. J Clin Oncol, 21:19 (2003), 3623–8., , , et al.
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol, 23:33 (2005), 8512–19., , , et al.
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer, 3: (2003), 26., , , et al.
Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ, 324:7341 (2002), 813., , , and
Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev, 1 (2002), CD002200., , and
Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum, 41:9 (1998), 1127–33., , , et al.
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol, 22:8 (2004), 1420–9., , , et al.
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer, 88:12 (2003), 1859–65., , , et al.
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol, 15:5 (1997), 2030–9., O' , , et al.
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control – final report of intergroup 0114. J Clin Oncol, 20:7 (2002), 1744–50., , , et al.
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of rectal cancer. Ann Oncol, 1: suppl. 16 (2005), i20–1. and